Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kodiak Sciences Inc.NASDAQ: KOD
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $66.22M (cash outflow) rose 7.8% year over year, behind the +13.5% change in trailing-twelve-month net income. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$196.36M (-14.6%) for the fiscal year ending Dec 2026, a slowdown from the +30.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$66.22M+0.9% QoQ
- Last fiscal yearDec 2025
- -$229.97M+30.5% YoY
- LTMSep 2026
- -$246.76M+13.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.8% | -1.8% | -9.5 pp |
| 1 year | +30.5% | -14.6% | -45.1 pp |
| 3-year CAGR | -11.7% | -33.7% | -22.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (229.97M) USD
- Year-over-year change
- -30.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (229.97M) | -30.5% |
| FY2024 | 2024-12-31 | (176.21M) | +32.4% |
| FY2023 | 2023-12-31 | (260.49M) | +22.0% |
| FY2022 | 2022-12-31 | (333.82M) | -25.0% |
| FY2021 | 2021-12-31 | (266.99M) | — |
Net Income vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.5% is the 5th highest of 10, against a peer median of -2.9%.
- Over three fiscal years its annual growth of -11.7% compares with a peer median of +20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.33B USD | -2.9% | +1.3% | 27.9% | |
| LTM Mar 2026 | $290.5M USD | +50.7% | +55.3% | 558.2% | |
| LTM Mar 2026 | $271.6M USD | +85.0% | +31.4% | 3566.6% | |
| LTM Sep 2026 | $246.76M USD | +13.5% | -11.7% | — | |
| LTM Jun 2026 | $167M USD | -36.5% | — | 3.1% | |
| LTM Mar 2026 | $160.9M USD | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | CHF 94.54M CHF | -8.3% | +34.7% | 18758.0% | |
| LTM Mar 2026 | $71.67M USD | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $60.96M USD | -388.6% | -1.9% | 18297.5% | |
BLTEBelite Bio, Inc | LTM Jun 2026 | $102.36K USD | +140.6% | +83.1% | — |
| Peer median (excluding KOD) | — | -2.9% | +20.3% | 1081.7% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 61.39M | 106.03M | 88.56M | 60.21M | 58.86M |
| Change in Working Capital | 14.43M | 11.96M | (7.36M) | (28.39M) | 6.85M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.09M) | 1.66M | 5.6M | (9.69M) | 8.07M |
| Other Working Capital | 16.52M | 10.3M | (12.95M) | (18.69M) | (1.22M) |
| Other Non-Cash Items | 198K | (1.63M) | (840K) | 355K | 1.93M |
| Operating Cash Flow | (182.27M) | (206.46M) | (154.18M) | (117.32M) | (136.01M) |
| Capital Expenditures | (63.3M) | (47.36M) | (41.43M) | (400K) | (506K) |
| Acquisitions (Net) | 0 | 0 | (290.65K) | 0 | 0 |
| Purchases of Investments | 0 | (427.77M) | (49.35M) | (355K) | 0 |
| Sales of Investments | 24.5M | 138M | 340M | 0 | 0 |
| Other Investing Activities | 0 | 616K | 290.65K | 0 | 0 |
| Investing Cash Flow | (38.8M) | (336.51M) | 249.23M | (755K) | (506K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 8.23M | 1.94M | 242K | 501K | 178.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45K) | (49K) | (211K) | 0 | 0 |
| Financing Cash Flow | 8.18M | 1.9M | 31K | 501K | 178.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (212.89M) | (541.08M) | 95.07M | (117.57M) | 41.79M |
| Free Cash Flow | (245.57M) | (253.82M) | (195.61M) | (117.72M) | (136.51M) |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.